Cerebrospinal Flt3 ligand correlates to tau protein levels in primary Sjögren’s syndrome

References

• Chai J, Logigian EL. Neurological manifestations of primary Sjögren’s syndrome. Curr Opin Neurol 2010;23:509–13.
   PubMed Web of Science ®Google Scholar
• Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 2004;83:280–91.
   PubMed Web of Science ®Google Scholar
• Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Ann Rev Biochem 2000;69:373–98.
   Google Scholar
• Chiba T, Yamada M, Aiso S. Targeting the JAK2/STAT3 axis in Alzheimer’s disease. Expert Opin Ther Targets 2009;13:1155–67.
   PubMed Web of Science ®Google Scholar
• Ko HS, Lee Y, Shin JH, Karuppagounder SS, Gadad BS, Koleske AJ, Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin’s ubiquitination and protective function. Proc Natl Acad Sci USA 2010;107:16691–6.
   PubMed Web of Science ®Google Scholar
• Fujita-Yoshigaki J, Matsuki-Fukushima M, Sugiya H. Inhibition of Src and p38 MAP kinases suppresses the change of claudin expression induced on dedifferentiation of primary cultured parotid acinar cells. Am J Physiol 2008;294:C774–85.
   Google Scholar
• Koski H, Konttinen YT, Hietanen J, Tervo T, Malmstrom M. Epidermal growth factor, transforming growth factor-alpha, and epidermal growth factor receptor in labial salivary glands in Sjögren’s syndrome. J Rheumatol 1997;24:1930–5.
   PubMed Web of Science ®Google Scholar
• Katz J, Stavropoulos F, Cohen D, Robledo J, Stewart C, Heft M. IGF- 1 and insulin receptor expression in the minor salivary gland tissues of Sjögren’s syndrome and mucoceles – immunohistochemical study. Oral Dis 2003;9:7–13.
   PubMedGoogle Scholar
• Servet-Delprat C, Arnaud S, Jurdic P, Nataf S, Grasset MF, Soulas C, Flt3+ macrophage precursors commit sequentially to osteoclasts, dendritic cells and microglia. BMC Immunol 2002;3:15.
   PubMedGoogle Scholar
• Nakamori Y, Liu B, Ohishi K, Suzuki K, Ino K, Matsumoto T, Human bone marrow stromal cells simultaneously support B and T/NK lineage development from human haematopoietic progenitors: a principal role for flt3 ligand in lymphopoiesis. Br J Haematol 2012;157:674–86.
   Google Scholar
• Sitnicka E, Brakebusch C, Martensson IL, Svensson M, Agace WW, Sigvardsson M, Complementary signaling through flt3 and interleukin-7 receptor alpha is indispensable for fetal and adult B cell genesis. J Exp Med 2003;198:1495–506.
   PubMed Web of Science ®Google Scholar
• Jensen CT, Kharazi S, Boiers C, Cheng M, Lubking A, Sitnicka E, FLT3 ligand and not TSLP is the key regulator of IL-7-independent B-1 and B-2 B lymphopoiesis. Blood 2008;112:2297–304.
   Google Scholar
• Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960–8.
   PubMed Web of Science ®Google Scholar
• Aloisi F. Immune function of microglia. Glia 2001;36:165–79.
   PubMed Web of Science ®Google Scholar
• Santambrogio L, Belyanskaya SL, Fischer FR, Cipriani B, Brosnan CF, Ricciardi-Castagnoli P, Developmental plasticity of CNS microglia. Proc Natl Acad Sci USA 2001;98:6295–300.
   PubMed Web of Science ®Google Scholar
• Brazel CY, Ducceschi MH, Pytowski B, Levison SW. The FLT3 tyrosine kinase receptor inhibits neural stem/progenitor cell proliferation and collaborates with NGF to promote neuronal survival. Mol Cell Neurosci 2001;18:381–93.
   Google Scholar
• Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570–80.
   PubMed Web of Science ®Google Scholar
• Ilzecka J. Cerebrospinal fluid Flt3 ligand level in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2006;114:205–9.
   PubMed Web of Science ®Google Scholar
• Tobon GJ, Renaudineau Y, Hillion S, Cornec D, Devauchelle-Pensec V, Youinou P, The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjögren’s syndrome. Arthritis Rheum 2010;62:3447–56.
   PubMed Web of Science ®Google Scholar
• King GD, Muhammad AK, Curtin JF, Barcia C, Puntel M, Liu C, Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro-oncology 2008;10:19–31.
   PubMed Web of Science ®Google Scholar
• Xiong W, Candolfi M, Liu C, Muhammad AK, Yagiz K, Puntel M, Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial. PloS One 2010;5:e11074.
   PubMed Web of Science ®Google Scholar
• Whartenby KA, Calabresi PA, McCadden E, Nguyen B, Kardian D, Wang T, Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci USA 2005;102:16741–6.
   PubMed Web of Science ®Google Scholar
• DeBoy CA, Rus H, Tegla C, Cudrici C, Jones MV, Pardo CA, FLT-3 expression and function on microglia in multiple sclerosis. Exp Mol Pathol 2010;89:109–16.
   Google Scholar
• Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131–44.
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554–8.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160–72.
   Google Scholar
• Diagnostic and statistical manual of mental disorders, 3rd edn, revised. Arlington, VA: American Psychiatric Association, 1987.
   Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44.
   PubMed Web of Science ®Google Scholar
• Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18:728–33.
   PubMed Web of Science ®Google Scholar
• Dehlin M, Bokarewa M, Rottapel R, Foster SJ, Magnusson M, Dahlberg LE, Intra-articular fms-like tyrosine kinase 3 ligand expression is a driving force in induction and progression of arthritis. PloS One 2008;3:e3633.
   Google Scholar
• Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231–45.
   PubMedGoogle Scholar
• Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjögren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49–52.
   PubMed Web of Science ®Google Scholar
• Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996;67:2013–18.
   PubMed Web of Science ®Google Scholar
• Rosengren LE, Wikkelso C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosc Methods 1994;51:197–204.
   PubMed Web of Science ®Google Scholar
• Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336–45.
   PubMed Web of Science ®Google Scholar
• Blennow K, Fredman P, Wallin A, Gottfries CG, Langstrom G, Svennerholm L. Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. Eur Neurol 1993;33:126–8.
   PubMed Web of Science ®Google Scholar
• Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord 2003;15:169–76.
   PubMed Web of Science ®Google Scholar
• Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 2007;78:461–4.
   PubMed Web of Science ®Google Scholar
• Mancuso M, Orsucci D, LoGerfo A, Calsolaro V, Siciliano G. Clinical features and pathogenesis of Alzheimer’s disease: involvement of mitochondria and mitochondrial DNA. Adv Exp Med Biol 2010;685:34–44.
   PubMed Web of Science ®Google Scholar
• Bazzichi L, Rossi A, Massimetti G, Giannaccini G, Giuliano T, De Feo F, Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol 2007;25:225–30.
   PubMed Web of Science ®Google Scholar
• Wang H, Moser M, Schiltenwolf M, Buchner M. Circulating cytokine levels compared to pain in patients with fibromyalgia – a prospective longitudinal study over 6 months. J Rheumatol 2008;35:1366–70.
   PubMed Web of Science ®Google Scholar
• Wallace DJ. Is there a role for cytokine based therapies in fibromyalgia. Curr Pharm Des 2006;12:17–22.
   PubMed Web of Science ®Google Scholar
• Gur A, Oktayoglu P. Status of immune mediators in fibromyalgia. Curr Pain Headache Rep 2008;12:175–81.
   PubMed Web of Science ®Google Scholar
• Petersel DL, Dror V, Cheung R. Central amplification and fibromyalgia: disorder of pain processing. J Neurosci Res 2011;89:29–34.
   PubMed Web of Science ®Google Scholar